Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14,390 JPY | -0.79% | -0.28% | -11.64% |
Apr. 12 | Cosmos Pharmaceutical's Attributable Profit Up 6.6% in Fiscal Nine Months | MT |
Apr. 12 | COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.56 for the 2024 fiscal year.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The firm trades with high earnings multiples: 22.81 times its 2024 earnings per share.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.64% | 3.62B | D+ | ||
-0.09% | 3.36B | D- | ||
-23.44% | 3.06B | D | ||
+7.56% | 2.67B | - | ||
+7.46% | 2.59B | C+ | ||
-9.26% | 1.75B | - | ||
+9.30% | 1.35B | - | - | |
-20.60% | 957M | - | ||
-38.42% | 704M | - | - | |
-1.85% | 370M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3349 Stock
- Ratings COSMOS Pharmaceutical Corporation